ReviewJournal of diabetes investigation2026
Proteostasis in the regulation of pancreatic islet cell plasticity.
Review in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Pancreatic islet cells continuously synthesize and secrete large quantities of peptide hormones, making them uniquely dependent on robust proteostasis networks to maintain cellular function. Traditionally, the unfolded protein response (UPR) is considered a stress-responsive pathway that protects cells from endoplasmic reticulum (ER) dysfunction or triggers apoptosis when ER stress is excessive. Here, we propose that proteostasis functions as an active physiological signaling network that governs islet cell adaptation, plasticity, and long-term homeostasis, extending beyond its conventional role in the response to cellular damage. In pancreatic β cells, glucose signaling suppresses the expression of the proapoptotic factor CHOP through both IRS2-dependent and IRS2-independent pathways, indicating that metabolic signaling directly remodels the ER stress response. In contrast, the CHOP-GADD34-eIF2α dephosphorylation axis constitutes a negative feedback mechanism that fine-tunes translational recovery and determines the balance between adaptation and cell death. Moreover, 4E-BP1-mediated inhibition of mRNA translation and modulation of mTOR signaling alleviate proteotoxic stress and promote β-cell survival under conditions of increased secretory demand. In addition to translational control, IGF2 receptor-mediated signaling has recently been implicated in the regulation of autophagy, further linking lysosomal quality control to β-cell proteostasis. Importantly, proteostasis also affects α-cell biology, where UPR signaling regulates glucagon secretion and contributes to α-to-β cell transdifferentiation, highlighting a previously unrecognized role of ER homeostasis in endocrine cell identity. Finally, recent findings indicate that progressive impairment of proteostasis is a hallmark of islet aging, integrating defects in protein folding, translation, autophagy, and stress adaptation into the pathogenesis of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.